

Supplement Documents for Financial Results Q1 FY12/20

May 15, 2020



To accelerate drug discovery and development of mAb
for therapeutics to overcome current medical unmet-needs

Chiome Bioscience Inc.

- 1. Overview of Q1 FY12/20 “Financial results”**
- 2. Overview of Q1 FY12/20 “Operation highlights”**

Appendix.

- Corporate information**
- Pipeline information**



Overview of Q1 FY12/20 “Financial results”



Financial results: Profit and Loss

(JPY in millions)

	Q1 FY2019	Q1 FY2020	Increase (decrease)	
Net sales	63	90	26	
Drug Discovery & Development	0	0	0	
Drug Discovery Support	63	89	26	• Growth in business with domestic pharmaceutical companies
COS/SGA	490	517	27	
R&D Expense	363	342	(20)	• Cost of GLP toxicology study and CMC development in CBA-1205
Other costs	127	174	47	• Costs of the expansion of laboratories and increasing equipment.
Operating Loss	(426)	(426)	0	
Ordinary Loss	(432)	(424)	(7)	
Net Loss	(430)	(425)	(5)	

Financial results: Balance Sheet

5



(JPY in millions)

	As of Dec. 31, 2019	As of Mar. 31, 2020
Current assets	2,561	2,309
(Cash on hand in banks)	2,105	1,967
(Other current assets)	456	342
Non-current assets	247	246
Total assets	2,808	2,556
Current Liabilities	145	315
Non-current liabilities	41	41
Total liabilities	186	356
Total net assets	2,621	2,199
Total liabilities and net assets	2,808	2,556



Overview of Q1 FY12/20 “Operation highlights”



Drug Discovery and Development Business

To discover and develop novel antibody drugs in-house or in collaboration with a partner up to late pre-clinical stage which enables to prepare data package for IND or early clinical stage in therapeutic areas where high unmet medical needs exist. The drug candidates will be out-licensed to pharmaceutical company under appropriate financial conditions such like upfront, milestone, and royalty payments etc.

Drug Discovery Support business


To provide “fee-for-service” to pharmaceutical and diagnostics company, and academia to support their research works. Main line of this business is 1) to generate a monoclonal antibody for their targets by our proprietary platform, and 2) to express, culture, and purify proteins including antigen and antibody.

Drug Discovery and Development -Pipeline

Out-Licensed Product

Code	Target	Therapeutic Area	Basic research, Drug Discovery	Preclinical Study	Clinical Trials	Partner
ADCT-701 (LIV-1205 ADC)	DLK-1	Oncology /ADC				

Pipelines

Project	Target	Therapeutic Area	Basic research, Drug Discovery	Preclinical Study	Clinical Trials	Status
CBA-1205 (ADCC enhanced)	DLK-1	Oncology				Developing in-house
CBA-1535 (Tribody)	5T4×CD3 ×5T4	Oncology				Developing in-house
LIV-2008 /2008b	TROP-2	Oncology				Licensing opportunity
BMAA	SEMA3A	DME, Others				 SemaThera (Exclusive option agreement)
Discovery PJ (6)	Undisclosed	Oncology infectious/ rare diseases				—

As of Mar. 31, 2020



CBA-1205

Humanized afucosylated anti-DLK1 antibody

- Initial application for a Phase I clinical trial was submitted to PMDA on Mar. 24. First-Patient-In (FPI) is expected in 2020.
- Filed new patent applications to increase potential therapeutic uses.

CBA-1535

Humanized anti 5T4/WAIF1 antibody, multi-specific antibody

- CMC development is planned with the timeline to submit CTA in the UK in the second half of 2021 onwards.
- Patent was granted in Japan on Apr. 22.

LIV-2008

Humanized anti-TROP2 antibody

- Under evaluation for in-licensing by several pharmaceutical companies.

BMAA

Humanized anti-Semphorin3A antibody

- Being evaluated by SemaThera Inc. under Collaborative Development License and Exclusive Option Agreement concluded in March 2018.

Discovery PJ

- Filed a new patent application for an oncology project.
- Feasibility study is being pursued aiming for potential collaboration with pharma companies.

ADCT-701

Out-Licensed Product

- ADC Therapeutics is continuing preparations for an IND.
- IND is expected to be submitted in 2020 or afterwards.

Business with pharmaceutical companies

- Sales increased 42% year-on-year due to increased business with domestic pharmaceutical companies.
- Recorded sales from antibody generation using the ADLib® system.

<Key business accounts>

Name of accounts	Entering date
Chugai Pharmaceutical Co., Ltd.	June 2011
Chugai Pharmabody Research Pte. Ltd.	August 2012
Mitsubishi Tanabe Pharma Corporation Tanabe Research Laboratories U.S.A., Inc.	December 2016
Ono Pharmaceutical Co., Ltd.	October 2018
Kyowa Kirin Co., Ltd.	July 2019

Topics

- Contract antibody generation project against COVID-19 in progress.


Despite changes, delays, and postponements of some operations made by the Company and its customers due to the spread of COVID-19, any impact on the financial performance for the current fiscal year has not been confirmed at this moment.

The Company's performance might be affected if the pandemic continues for a long period of time, causing the Company, research institutes, and business partners to suspend their businesses, close facilities, or delay procedures by authorized agencies in the country or region in which the Company conducts business.

The Company is currently conducting business under a business contingency plan that includes remote working and flexible work shift to cope with the spread of COVID-19.

Appendix. Corporate information

Biotech company dedicating to satisfy unmet medical needs



Management principle

- Place the highest priority on sound management and credibility and aim to become a corporation that grows with society.
- With creativity and science, develop therapeutic drugs for unmet medical needs, and contribute to the health of patients.
- Achieve successive product pipelines and improvement of corporate value through collaboration with external institutions.

■ Founded: February 2005

■ Listed on the stock exchange: Dec.2011 (Tokyo Stock Exchange Mothers Section) 


■ President and Chief Executive Officer: Shigeru Kobayashi, M.E.

■ Location :
<Head Office and Research Laboratories>
3-12-1 Honmachi, Shibuya-ku, Tokyo
<Drug Discovery Laboratories>
2-13-3 Nogawahonchou, Miyamae-ku,
Kawasaki-city, Kanagawa

■ Number of Employees : 57 (As of Mar. 31,2020)

■ Business : Chiome Bioscience (4583.T), is a public company leveraging a proprietary monoclonal antibody generating technology, for drug discovery and development, as well as providing drug discovery supports.

Technology Platform (Chiome's mAb Discovery Engine)



Chiome possesses antibody platforms including its proprietary technology, and extensive know-hows and experiences in protein/antibody engineering to streamline the process of drug discovery.

This enables us to contribute in


Drug Discovery and Development

Development of therapeutic drug and diagnostic agent

Drug Discovery Support


Contract service for drug discovery

Drug development process and Chiome's revenue model



Drug Discovery

Revenues by licensing-out patents of pipeline product and drug candidates to pharmaceutical companies.




Drug Discovery Support

Revenues by providing drug discovery supporting services to pharmaceutical and diagnostics company, and academia.



Core technology will sustain continuous development of therapeutic antibody while offering higher quality of service





Appendix. Pipeline information

ADCT-701* (Humanized anti-DLK1 antibody ADC)

- ✓ An Antibody Drug Conjugate (ADC) form of LIV-1205 that was licensed out to Switzerland-based ADC Therapeutics SA in September 2017.
- ✓ ADCT has completed pharmacology and toxicology studies required for an IND submission and is continuing preparations for an Investigational New Drug Application (IND).

*Chiome granted ADCT a worldwide exclusive license with a right to sublicense, develop, manufacture, and commercialize an ADC format of LIV-1205, which is coded “ADCT-701”.




CBA-1205 (Humanized afucosylated anti-DLK1 antibody)

First in class

- ✓ A humanized antibody generated by hybridoma technology in Livtech which Chiome acquired in 2015.
- ✓ Therapeutic Area : Liver cancer, lung cancer, neuroblastoma etc.
- ✓ Patent : Granted in Japan, US, Europe, China etc.
- ✓ Unmet needs that we should satisfy : Providing new therapeutics for highly malignant tumors without effective therapeutic drugs including hepatocellular carcinoma.

CBA-1535 (Humanized anti 5T4 antibody, multi-specific antibody)

- ✓ CBA-1535 is a T-cell engager, trispecific antibody, directed against the 5T4 tumor antigen, a protein found on various solid tumors and is thought to be involved in metastasis.
- ✓ Therapeutic Area : Malignant mesothelioma, small cell lung cancer, non small cell lung cancer, TNBC etc.
- ✓ Patent : Granted in Japan, Pending in US, Europe etc.



LIV-2008 (Humanized anti-TROP2 antibody)

- ✓ LIV-2008 is a humanized monoclonal antibody targeting cell surface antigen "TROP-2" which is overexpressed in breast cancer, colon cancer, lung cancer and several types of solid cancers and also expected to play a key role in the proliferation of cancer cells.
- ✓ Therapeutic Area : Breast cancer (TNBC), lung cancer, colorectal cancer etc.
- ✓ Patent : Granted in Japan, US, EU, China etc.

BMAA (Humanized anti-Semaphorin3A antibody)

First in class

- ✓ A humanized antibody generated using the ADLib® System.
- ✓ Chiome has granted SemaThera Inc. an exclusive option right to obtain a worldwide exclusive license to develop the antibody as a therapeutic and/or diagnostic agent.
- ✓ Therapeutic Area : Diabetic macular edema (DME)
- ✓ Patent : Granted in Japan, US and Europe etc.





Shine light on unmet needs. Bring a brighter future to patients.

To accelerate drug discovery and development of mAb
for therapeutics to overcome current medical unmet-needs





- Materials and information provided during this presentation may contain so-called “forward-looking statements.” These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements.
- Risks and uncertainties include general industry and market conditions, and general domestic and international economic conditions such as interest rate and currency exchange fluctuations.
- The Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.